Papp A C, Hatzakis H, Bracey A, Wu K K
Vascular Disease Research Center, University of Texas Health Science, Houston.
Thromb Haemost. 1989 Feb 28;61(1):15-9.
In order to carry out a multicenter study aimed at understanding the association of hemostatic factors with atherosclerotic vascular disorders for the Atherosclerosis Risk In Communities (ARIC) Study, we compared a blood collection and processing system developed in our laboratory with the state-of-the-art-procedures. The salient features of our system included the use of a new phlebotomy set for venipuncture, the use of Millipore filters for removing platelet residues in the plasma and the use of a mixture of anticoagulants and antiplatelet agents for inhibiting the in vitro activation of platelets, coagulation and fibrinolytic system. The results derived from systematic evaluations indicate that this newly developed system yields the lowest values of plasma beta TG, PF 4 and FPA when compared with the reported values. The technique also gave reliable values of representative hemostatic measurements such as fibrinogen, factor VII, factor VIII, von Willebrand factor, antithrombin-III, protein C, tissue-type plasminogen activator, and serum thromboxane B2. Further experiments revealed that the samples withstood temporary storage at -70 degrees C and overnight "shipping" manipulations without significant changes in the hemostatic values. We conclude that the described blood collection and processing system may be a valuable asset for conducting multicenter cooperative clinical trials and epidemiologic studies involving blood collection by multiple field centers or clinics.
为了开展一项多中心研究，旨在了解社区动脉粥样硬化风险（ARIC）研究中止血因素与动脉粥样硬化性血管疾病的关联，我们将实验室开发的血液采集和处理系统与最先进的程序进行了比较。我们系统的显著特点包括使用一种新的静脉穿刺采血套件、使用密理博过滤器去除血浆中的血小板残留物，以及使用抗凝剂和抗血小板剂的混合物来抑制血小板、凝血和纤溶系统的体外激活。系统评估得出的结果表明，与报告值相比，这种新开发的系统产生的血浆β-血小板球蛋白、血小板第4因子和纤维蛋白肽A值最低。该技术还给出了代表性止血测量的可靠值，如纤维蛋白原、凝血因子VII、凝血因子VIII、血管性血友病因子、抗凝血酶III、蛋白C、组织型纤溶酶原激活剂和血清血栓素B2。进一步的实验表明，样本在-70摄氏度下临时储存和过夜“运输”操作后，止血值没有显著变化。我们得出结论，所述的血液采集和处理系统可能是开展涉及多个现场中心或诊所采血的多中心合作临床试验和流行病学研究的宝贵资产。
